Relmada Therapeutics to Present at Jefferies London Healthcare Conference
Relmada Therapeutics to Present at Jefferies London Healthcare Conference
The replay of the webcast will be available on the "For Investors/Events" page of the Relmada website for 90 days following the conference. Conference being held November 19-21, 2024
會議將於 2024 年 11 月 19 日至 21 日舉行
CORAL GABLES, Fla., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, "Relmada", "the Company"), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that Sergio Traversa, Chief Executive Officer (CEO), will present at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024.
佛羅里達州科勒爾蓋布爾斯，2024年11月19日（環球新聞專線）——針對中樞神經系統疾病（CNS）的後期生物技術公司Relmada Therapeutics, Inc.（納斯達克股票代碼：RLMD，「Relmada」，「公司」）今天宣佈，首席執行官（CEO）塞爾吉奧·特拉弗薩將於2024年11月20日星期三出席傑富瑞倫敦醫療會議。
Jefferies London Healthcare Conference details:
傑富瑞倫敦醫療保健會議詳情：
| Presentation: | Wednesday, November 20, 2024 at 12:00 PM GMT |
| Speaker: | Sergio Traversa, CEO |
| Registration: | Webcast link |
| 演示文稿： | 格林尼治標準時間 2024 年 11 月 20 日星期三下午 12:00 |
| 揚聲器： | 首席執行官塞爾吉奧·特拉弗薩 |
| 註冊： | 網絡直播鏈接 |
The replay of the webcast will be available on the "For Investors/Events" page of the Relmada website for 90 days following the conference.
網絡直播的重播將在會議結束後的90天內在Relmada網站的 「投資者/活動專區」 頁面上播放。
About Relmada Therapeutics, Inc.
關於 Relmada Therapeutics, Inc.
Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Relmada's experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada's lead program, REL-1017, is a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 is in late-stage development as an adjunctive treatment for MDD in adults. The Company is also developing REL-P11, a proprietary low-dose psilocybin, as an investigational agent for metabolic disease. Learn more at .
Relmada Therapeutics是一家處於後期階段的生物技術公司，主要研究中樞神經系統疾病（CNS），專注於重度抑鬱症（MDD）。Relmada經驗豐富、敬業的團隊致力於改變患者及其家屬的生活。Relmada的主要項目 REL-1017 是一種新的化學實體（NCE）和新型的NMDA受體（NMDAR）通道阻滯劑，它優先靶向過度活躍通道，同時保持生理穀氨酸能神經傳遞。作爲成人 MDD 的輔助治療方法，REL-1017 處於後期開發階段。該公司還在開發專有的低劑量迷幻藥 REL-P11，作爲代謝性疾病的研究藥物。要了解更多，請訪問。
Investor Contact:
Tim McCarthy
LifeSci Advisors
Tim@LifeSciAdvisors.com
投資者聯繫人：
蒂姆·麥卡錫
生命科學顧問
Tim@LifeSciAdvisors.com
Media Inquiries:
Corporate Communications
media@relmada.com
媒體查詢：
企業傳播
media@relmada.com
